The authors proposed the use of thymopentin, a new immunomodulating drug, for the treatment of herpes zoster. The observations in 53 subjects treated with thymopentin and 90 patients treated with traditional therapy highlighted the ability of the drug to reduce the duration of the disease and scabbing time. The early start of therapy produced a notable reduction of the pain characteristic of herpes zoster. On the basis of their observations, the authors assumed that thymopentin possesses an antiphlogistic activity.
|Number of pages||7|
|Journal||Current Therapeutic Research|
|Publication status||Published - 1988|
ASJC Scopus subject areas